NasdaqGM:AQST
NasdaqGM:AQSTPharmaceuticals

Aquestive Therapeutics (AQST): A Fresh Look at Valuation After FDA Advances Sublingual Epinephrine Film

If you have been eyeing Aquestive Therapeutics (AQST), recent developments may prompt you to take another look. The buzz centers on news that the FDA has waived the advisory committee meeting for Anaphylm, the company’s sublingual epinephrine film for severe allergic reactions. For investors, this move is significant, as it generally signals reduced regulatory hurdles and greater confidence in an eventual approval. The major Prescription Drug User Fee Act decision date is now set for January...
NYSE:JBI
NYSE:JBIBuilding

Does Goldman Sachs’ Exit and Institutional Shifts Signal a Strategic Turning Point for Janus International (JBI)?

In the first quarter of this year, Goldman Sachs Group Inc. reduced its position in Janus International Group, Inc. by over half, selling 609,259 shares, while other major investors, including American Century Companies Inc. and Epoch Investment Partners Inc., made significant changes to their holdings. This reshuffling among top institutional shareholders, paired with mixed analyst ratings and an upgrade from hold to buy, reflects shifting views on the company's prospects. We'll examine how...
NasdaqCM:MLGO
NasdaqCM:MLGOIT

Can MicroAlgo's (MLGO) Higher Profits Amid Falling Sales Reveal a Sustainable Efficiency Advantage?

MicroAlgo Inc. recently reported its earnings for the half year ended June 30, 2025, revealing revenue of CNY 188.11 million compared to CNY 290.44 million a year earlier, alongside net income of CNY 26.47 million up from CNY 16.26 million. The company’s net income growth despite significantly lower revenue suggests possible improvements in cost control or operational efficiency during the period. We will explore how MicroAlgo’s ability to improve net income amid decreased sales shapes its...
NYSE:LDI
NYSE:LDIDiversified Financial

How Do Insider Sales Shape loanDepot's (LDI) Turnaround Credibility Under "Vision 2025"?

Earlier this month, loanDepot, Inc. filed a US$24.9 million shelf registration for 5,874,020 shares of Class A Common Stock, specifically for an ESOP-related offering, while directors and PCP Managers, L.P. sold a combined US$5.96 million in stock and the company completed a US$150 million term notes offering backed by mortgage servicing rights. These developments come as loanDepot continues its “Vision 2025” turnaround plan, with narrowing net losses, substantial liquidity of over US$400...